Mason & Associates (California)’s Recursion Pharmaceuticals RXRX Stock Holding History

Mason & Associates (California)’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$94.6K	Buy	33,300 +135	+0.4%	+$522	0.02%	159
2025 Q4	$136K	Hold	33,165	–	–	0.03%	156
2025 Q3	$162K	Hold	33,165	–	–	0.03%	132
2025 Q2	$168K	Hold	33,165	–	–	0.04%	120
2025 Q1	$175K	Buy	+33,165	New	+$242K	0.04%	113

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mason & Associates (California)'s RXRX Position: Q1 2026 in Review

Mason & Associates (California) increased its Recursion Pharmaceuticals (RXRX) stake by 0.41% in Q1 2026, buying an estimated $522 and bringing the position to 33,300 shares worth $94.6K. The position accounts for 0.02% of the portfolio, ranked #159.

Mason & Associates (California) first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $175K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Mason & Associates (California) held 33,300 shares of Recursion Pharmaceuticals worth $94.6K as of Q1 2026.
Mason & Associates (California) bought 135 Recursion Pharmaceuticals shares in Q1 2026, an estimated $522.
Recursion Pharmaceuticals made up 0.02% of Mason & Associates (California)'s portfolio in Q1 2026, its #159 holding.
Mason & Associates (California) first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
Mason & Associates (California)'s Recursion Pharmaceuticals position peaked at $175K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Mason & Associates (California)'s 13F filing for Q1 2026, filed 30 Apr 2026.